Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
Phase 2
Active, not recruiting
- Conditions
- Fetal and Neonatal Alloimmune Thrombocytopenia
- Interventions
- Drug: Anti-(integrin beta-3) human monoclonal antibody
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Rallybio
- Target Recruit Count
- 8
- Registration Number
- NCT06435845
- Locations
- 🇳🇱
Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
🇳🇴Oslo University Hospital- Ullevål, Oslo, Norway
🇸🇪Södersjukhuset, Stockholm, Sweden
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
Active, not recruiting
- Conditions
- Fetal and Neonatal Alloimmune Thrombocytopenia
- Interventions
- Other: Clinical data collection
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Rallybio
- Target Recruit Count
- 30000
- Registration Number
- NCT05345561
- Locations
- 🇺🇸
Javara Research Inc. - Dallas - PPDS, Houston, Texas, United States
🇳🇴Universitetssykehuset Nord Norge, Tromsø, Norway
🇸🇪Barnmorskestationen Rosengård, Lund, Skane, Sweden
© Copyright 2025. All Rights Reserved by MedPath